70547-50-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as a potential active pharmaceutical ingredient for its diverse biological activities. Its antimicrobial, antiviral, antifungal, anticancer, and anti-inflammatory properties make it a promising candidate for the development of new drugs to treat various diseases and conditions.
Used in Antimicrobial Applications:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as an antimicrobial agent to combat bacterial infections. Its ability to inhibit the growth of bacteria makes it a valuable compound in the development of new antibiotics to address the growing issue of antibiotic resistance.
Used in Antiviral Applications:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as an antiviral agent to inhibit the replication of viruses, providing a potential treatment for viral infections. Its antiviral properties can be harnessed to develop new antiviral drugs to combat various viral diseases.
Used in Antifungal Applications:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as an antifungal agent to treat fungal infections. Its ability to inhibit the growth of fungi makes it a valuable compound in the development of new antifungal drugs to address the increasing prevalence of drug-resistant fungal infections.
Used in Anticancer Applications:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as an anticancer agent to target and inhibit the growth of cancer cells. Its potential to interfere with cancer cell proliferation and survival pathways makes it a promising compound for the development of new cancer therapies.
Used in Anti-inflammatory Applications:
5-Methyl-2-(4-pyridinyl)-1,3-thiazol-4-ol is used as an anti-inflammatory agent to reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its ability to modulate inflammatory responses can be utilized in the development of new treatments for various inflammatory diseases.

InChI:InChI=1/C9H8N2OS/c1-6-8(12)11-9(13-6)7-2-4-10-5-3-7/h2-5,12H,1H3

Upstream product

• 100-48-1 pyridine-4-carbonitrile 
• 79-42-5 2-mercaptopropanoic acid 
• 6959-64-4 (+)-thiolactic acid 
• 5445-17-0 Methyl 2-bromopropionate 
• 2196-13-6 pyridine-4-carbothioamide 

Downstream Products

• 1279106-62-5 Benzenesulfonyl-2-(2,6-difluoro-phenyl)-5-(5-methyl-2-pyridin-4-yl-thiazol-4-yl)-1H-indole 
• 1279103-58-0 2-(2,6-difluoro-phenyl)-5-(5-methyl-2-pyridin-4-yl-thiazol-4-yl)-1H-indole 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands

Histamine H3 receptor (H3R) is largely expressed in the CNS and modulation of the H3R function can affect histamine synthesis and liberation, and modulate the release of many other neurotransmitters. Targeting H3R with antagonists/inverse agonists may have therapeutic applications in neurodegenerative disorders, gastrointestinal and inflammatory diseases. This prompted us to design and synthesize azole-based H3R ligands, i.e. having oxadiazole- or thiazole-based core structures. While ligands of oxadiazole scaffold were almost inactive, thiazole-based ligands were very potent and several exhibited binding affinities in a nanomolar concentration range. Ligands combining 4-cyanophenyl moiety as arbitrary region, para-xylene or piperidine carbamoyl linkers, and/or pyrrolidine or piperidine basic heads were found to be the most active within this series of thiazole-based H3R ligands. The most active ligands were in silico screened for ADMET properties and drug-likeness. They fulfilled Lipinski's and Veber's rules and exhibited potential activities for oral administration, blood–brain barrier penetration, low hepatotoxicity, combined with an overall good toxicity profile.

ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS

The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

BENZOXAZINE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Hydroxythiazole-based fluorescent probes for fluoride ion detection

This work describes the synthesis of five O-silyloxy-1,3-thiazoles and their use as fast-response "turn-on" probes for fluoride ion detection in polar aprotic solvents and in aqueous cetyltrimethylammonium bromide micellar medium. The fluoride-triggered d

INDOLE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS

A composition for the inhibition of lipoxygenase enzymes comprising a pharmaceutically acceptable carrier and a compound of the formula: I wherein R1 and R2 are independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl,

4-Hydroxythiazole Inhibitors of 5-Lipoxygenase

4-Hydroxythiazoles have been identified as potent inhibitors of 5-lipoxygenase in vitro exhibiting IC50's of less than 1 μM.An investigation of structure-activity relationships showed that the most potent inhibitors of this series are the 5-phenyl derivatives.The corresponding thiazolidin-4-one analogues were found to be relatively inactive.The 4-hydroxythiazoles were active inhibitors against 5-lipoxygenase in both intact rat polymorphonuclear leukocytes and human whole blood.The compounds were also selective inhibitors of 5-lipoxygenase, displaying only weak activity against other related enzymes, cyclooxygenase and 12- and 15-lipoxygenase.